Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;82(2):102-117.
doi: 10.4046/trd.2018.0091. Epub 2019 Feb 28.

Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis

Sang Hoon Lee  1 , Yoomi Yeo  2 , Tae Hyung Kim  2 , Hong Lyeol Lee  3 , Jin Hwa Lee  4 , Yong Bum Park  5 , Jong Sun Park  6 , Yee Hyung Kim  7 , Jin Woo Song  8 , Byung Woo Jhun  9 , Hyun Jung Kim  10 , Jinkyeong Park  9 , Soo Taek Uh  11 , Young Whan Kim  12 , Dong Soon Kim  8 , Moo Suk Park  13 ; Korean Interstitial Lung Diseases Study Group
Affiliations
Review

Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis

Sang Hoon Lee et al. Tuberc Respir Dis (Seoul). 2019 Apr.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia, which presents with a progressive worsening dyspnea, and thus a poor outcome. The members of the Korean Academy of Tuberculosis and Respiratory Diseases as well as the participating members of the Korea Interstitial Lung Disease Study Group drafted this clinical practice guideline for IPF management. This guideline includes a wide range of topics, including the epidemiology, pathogenesis, risk factors, clinical features, diagnosis, treatment, prognosis, and acute exacerbation of IPF in Korea. Additionally, we suggested the PICO for the use of pirfenidone and nintendanib and for lung transplantation for the treatment of patients with IPF through a systemic literature review using experts' help in conducting a meta-analysis. We recommend this guideline to physicians, other health care professionals, and government personnel in Korea, to facilitate the treatment of patients with IPF.

Keywords: Diagnosis; Disease Management; Idiopathic Pulmonary Fibrosis; Korea.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1. High resolution computed tomography images demonstrating usual interstitial pneumonia (arrows) (A) and possible usual interstitial pneumonia (arrows) (B) (Courtesy from Ulsan College of Medicine, Asan Medical Center, Internal Medicine, Prof. Song JW).
Figure 2
Figure 2. Surgical lung biopsy specimen demonstrating usual interstitial pneumonia pattern (Courtesy from Yonsei University, College of Pathology Prof. Sim HS).
Figure 3
Figure 3. Forest plot of the risk difference of percentage of study population with forced vital capacity decreased by more than 10%. CI: confidence interval.
Figure 4
Figure 4. Difference in annual forced vital capacity decline rate between nintedanib and placebo groups. CI: confidence interval.
Figure 5
Figure 5. Difference in survival between lung transplantation and placebo groups. OR: odds ratio; CI: confidence interval.
Figure 6
Figure 6. Diagnostic algorism of acute respiratory deterioration in idiopathic pulmonary fibrosis patients. IPF: idiopathic pulmonary fibrosis; GGO: ground glass opacity; CT: computed tomography.
See this image and copyright information in PMC

References

    1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. - PMC - PubMed
    1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304. - PubMed
    1. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3–e19. - PubMed
    1. Scientific Committee of the Korean Academy of Tuberculosis and Respiratory Diseases. 2008 National survey of idiopathic interstitial pneumonia in Korea. Tuberc Respir Dis. 2009;66:141–151.
    1. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150:967–972. - PubMed